1-3 of 3
Robert Corringham, MD
Close
Sort by
Journal Articles

A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

Jorge E. Cortes, Alexander E Perl, MD, Catherine C. Smith, MD, Tibor Kovacsovics, MD, Herve Dombret, Hartmut Dohner, MD, Bjorn Steffen, MD, Arnaud Pigneux, MD, PhD, Philippe Rousselot, MD, PhD, Juergen Krauter, MD, Giovanni Martinelli, MD, Elihu H. Estey, MD, Alan K Burnett, MD, Anthony D. Ho, Norbert Ifrah, Theo de Witt, MD, Robert Corringham, MD, Joyce James, PhD, David Lilienfeld, MD, Eugen Leo, MD, PhD, MBA, Guy Gammon, MD, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2576.
https://doi.org/10.1182/blood.V118.21.2576.2576
Published: 2011
Journal Articles

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jorge Cortes, MD, James Foran, MD, Darejan Ghirdaladze, MD, PhD, Marcel P DeVetten, MD, Mamia Zodelava, MD, PhD, Peter Holman, MD, Mark J Levis, MD, PhD, Hagop M Kantarjian, MD, Gautam Borthakur, MD, Joyce James, PhD, Patrick P Zarringkar, PhD, Ruwanthi N Gunawardane, PhD, Robert C Armstrong, PhD, Norman M Padre, Wendell Wierenga, PhD, Robert Corringham, MD, Mohit Trikha, PhD
Journal: Blood
Blood (2009) 114 (22): 636.
https://doi.org/10.1182/blood.V114.22.636.636
Published: 2009
Journal Articles

Inhibition of Interleukin-6 Signaling with CNTO328 Sensitizes Multiple Myeloma Cells to Bortezomib and Attenuates Proteasome Inhibitor-Mediated Induction of the Anti-Apoptotic Heat Shock Protein Response.

Peter M. Voorhees, MD, Deborah J. Kuhn, PhD, George W. Small, PhD, John S. Strader, PA, Robert Corringham, MD, Mohamed H. Zaki, MD, PhD, Jeffrey Nemeth, PhD, Robert Z. Orlowski, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 1574.
https://doi.org/10.1182/blood.V106.11.1574.1574
Published: 2005